Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Published:2017-03 Issue:3 Volume:23 Page:428-435
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Kolstad Arne,Pedersen Lone Bredo,Eskelund Christian W.,Husby Simon,Grønbæk Kirsten,Jerkeman Mats,Laurell Anna,Räty Riikka,Elonen Erkki,Andersen Niels Smedegaard,Brown Peter deNully,Kimby Eva,Bentzen Hans,Sundström Christer,Ehinger Mats,Karjalainen-Lindsberg Marja-Liisa,Delabie Jan,Ralfkiær Elisabeth,Fagerli Unn-Merete,Nilsson-Ehle Herman,Lauritzsen Grete Fossum,Kuittinen Outi,Niemann Carsten,Geisler Christian Hartman

Funder

Nordic Cancer Union

Danish Cancer Society

Bayer Schering

Norwegian Cancer Society

Kristian Gerhard Jebsen Foundation

Oslo University Hospital

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference30 articles.

1. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma;Robinson;Leukemia,2015

2. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle-cell lymphoma;Khouri;J Clin Oncol,1998

3. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

4. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group;Geisler;Blood,2008

5. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma;2023-12-08

3. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-12

4. Measurable Residual Disease Monitoring in Lymphoma;Current Hematologic Malignancy Reports;2023-11-06

5. Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies;Clinical Lymphoma Myeloma and Leukemia;2023-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3